Australia has one authority and a clear guideline. India has seven overlapping regimes, no plain-language guide, and enforcement split between a medical body, a consumer body, state drug controllers and the courts.
Most Indian healthcare marketing happens in the gap between them. That works until it does not.
No commissions for referrals. In any form, under any description. This has been prohibited for decades, it survived every change to the rules, and it is where a great deal of Indian medical marketing quietly sits.
If money moves per patient delivered rather than for clinical work performed, the arrangement is in a contested category and the marketing is the smallest part of the problem. We will not build anything on that structure.
What is safe: explaining a condition honestly, showing your doctors, publishing what you treat and what you refer elsewhere. Education is not soliciting. Promising to fix someone is.
If your prescription disclaimers, terms or marketing policy cite the "NMC 2023 Regulations", they cite rules that were paused in August 2023 and never revived. It is a one-hour fix and it is the kind of detail a lawyer notices.
Every page, every social account, and the paperwork — checked against all seven regimes, with the risky items ranked first.